• linkedin
  • Increase Font
  • Sharebar

    Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DME

    Anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line treatment in the United States that physicians treat patients with decreased vision due to diabetic macular edema (DME), with an overwhelming 95% choosing an anti-VEGF drug.

    Dr. Ciulla

    Specifically, bevacizumab (Avastin, Genentech) was the runaway favorite over ranibizumab (Lucentis, Genentech), and aflibercept (Eylea, Regeneron Pharmaceuticals), according to the 2016 Preferences & Trends Survey of the American Society of Retina Specialists.

    The DRCR Protocol T indicated that among these 3 agents, patients gained an average of 12 letters of vision after 2 years. Another important finding was that patients with worse visual acuity at baseline achieved more visual acuity improvements than those with better visual acuity at baseline.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';